← Back to Search

Other

Perfusion with Indocyanine green for Shoulder Replacement Surgery (ICG Trial)

N/A
Waitlist Available
Led By John-Erik Bell, MD
Research Sponsored by Dartmouth-Hitchcock Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, up to 2 hours
Awards & highlights

ICG Trial Summary

This trial is testing a new way to image blood flow during shoulder surgery, in order to improve patient outcomes.

Eligible Conditions
  • Shoulder Replacement Surgery
  • Shoulder Arthritis
  • Shoulder Pain

ICG Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, up to 2 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, up to 2 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
measurement of change to tendon blood supply during total shoulder arthroplasty
Secondary outcome measures
measurement of change to tendon blood supply using different techniques used in total shoulder arthroplasty

ICG Trial Design

1Treatment groups
Experimental Treatment
Group I: patients requiring a shoulder arthroplastyExperimental Treatment1 Intervention
Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an FDA approved imaging system.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perfusion with Indocyanine green
2022
N/A
~10

Find a Location

Who is running the clinical trial?

Dartmouth-Hitchcock Medical CenterLead Sponsor
524 Previous Clinical Trials
2,543,329 Total Patients Enrolled
John-Erik Bell, MDPrincipal InvestigatorDartmouth-Hitchcock Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is participation in this experiment open to the public?

"As per clinicaltrials.gov, this study has ceased to accept participants as of December 17th 2021. The trial began recruiting on March 1st 2022 and is now one of 84 other medical trials still looking for patients."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Subscapularis Indocyanine Green Perfusion Pilot Study
John-Erik Bell 2022. "Subscapularis Indocyanine Green Perfusion Pilot Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05179941.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top